2:33 PM
 | 
May 11, 2018
 |  BioCentury  |  Finance

Seroquel stepping stone

How Luye will use Seroquel to expand in emerging markets

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline.

On May 7, Luye licensed exclusive rights to market the dibenzothiazepine atypical antipsychotic and its extended-release formulation, Seroquel XL, in 51 countries spanning developed and emerging markets. While Luye already markets products in developed and some emerging markets such as Russia and Indonesia, the deal will give Luye access to additional emerging markets...

Read the full 416 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >